KDR and cancer: Figure 12B showed that compounds 20 and 21 were linked to the binding site of c-Met kinase, and quinazoline formed hydrogen bond interactions with MET-1160 [72]. All results indicated that compounds 20 and 21 were dual-target VEGFR-2/c-Met kinase inhibitors that held promising potential in cancer therapy.